Medical Enterprises Group is a growing medical device company focused on developing minimally invasive therapeutic technologies which provide benefits for both patients​ and the healthcare system.



Our Representatives

Naama Reich

Marketing Executive, Mel Medical Enterprises

Marketing Executive

Mel Medical Enterprises

Our company is focused on developing minimally invasive therapeutic technologies. Medical Enterprises has always offered to its partners product of high quality, through research and care...

Company Solutions

Synergo®, our lead product, is a minimally-invasive treatment option for non-muscle invasive bladder cancer (NMIBC) - one of the most common cancers in the world.

It is a powerful tri-modality consisting of local radiofrequency (microwave), chemotherapy, and hyperthermia (targeted directly at the bladder tissue).

Synergo®'s transurethral RF applicator (disposable set) is equipped with an embedded, miniaturized antenna, 5 thermocouples (precise thermometers), and tubing lines for the circulation of the chemotherapy from the device to the bladder and back, for its cooling and stability. The chemotherapy circulated is the same as the one routinely used by urologists, however, the administration via Synergo® vastly potentiates it, resulting in a considerably higher efficacy and favorable clinical outcomes.

With over 50 publications, including randomized controlled trials and a recommendation in the European Association of Urology guidelines, the treatment has proven to reduce recurrences and the need for repetitive surgical interventions, and for most indicated patients, it may even spare a cystectomy (the removal of the bladder). It has become a well-established option for clinicians to offer their patients with bladder cancer.

Looking For

  • Distributors
  • Agents
  • Investors
  • Strategic Partners